Kitakaze, Masatoshi
Uemura, Mamoru
Hara, Tomoaki
Chijimatsu, Ryota
Motooka, Daisuke
Hirai, Toshiro
Konno, Masamitsu
Okuzaki, Daisuke http://orcid.org/0000-0002-4552-783X
Sekido, Yuki
Hata, Tsuyoshi
Ogino, Takayuki
Takahashi, Hidekazu http://orcid.org/0000-0003-0779-407X
Miyoshi, Norikatsu
Ofusa, Ken
Mizushima, Tsunekazu http://orcid.org/0000-0002-0825-6823
Eguchi, Hidetoshi
Doki, Yuichiro
Ishii, Hideshi http://orcid.org/0000-0002-0632-6517
Funding for this research was provided by:
Ministry of Education, Culture, Sports, Science and Technology (20H00541, 18KK0251, 19K22658, 21K19526, 22H03146, 22K19559, 16H06279 (PAGS), 22H04925 (PAGS))
Mitsubishi Foundation (2021)
Japan Agency for Medical Research and Development (17cm0106414h0002, JP21lm0203007)
Article History
Received: 18 January 2022
Revised: 30 January 2023
Accepted: 6 February 2023
First Online: 3 March 2023
Competing interests
: Institutional endowments were received from Taiho Pharmaceutical Co., Ltd., Unitech Co., Ltd. (Chiba, Japan), IDEA Consultants, Inc. (Tokyo, Japan), and Kinshu-kai Medical Corporation (Osaka, Japan) (H Ishii); Chugai Co., Ltd., Yakult Honsha Co., Ltd., and Merck & Co., Ltd (M Konno). KO is an employee of IDEA Consultants Inc. (Tokyo, Japan).
: Not applicable.
: Written informed consent was obtained from all patients for the use of their samples and data.